CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 95 enrolled
Drug / intervention
Bevacizumabdrug
Likely dose
Bevacizumab 15 milligramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01588184
NCT01588184Phase 4Completed
CompareCT.gov

A Single Arm, Open Label Multicentre Extension Study of Bevacizumab in Patients With Solid Tumours on Study Treatment With Bevacizumab, at the End of A F. Hoffmann-La Roche and/or Genentech Sponsored Study

Hoffmann-La Roche·interventional·Posted Apr 30, 2012·Updated Nov 5, 2020

In Brief

A Phase 4 clinical trial evaluating Bevacizumab for Neoplasms. Completed, enrolled 95 participants across 73 sites in 21 countries.

Detailed Summary

This single-arm, open-label, multicenter extension study will provide continued bevacizumab therapy to participants with solid tumors who were previously enrolled in a Roche/Genentech sponsored study and who derived benefit from the bevacizumab therapy. Participants will receive the same dose and regimen of bevacizumab as used in the previous parent trial and continue this treatment until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeoplasms
CountriesAustria, Brazil, Bulgaria, Canada, Czechia, Estonia, France, Germany, Hungary, Italy, Mexico, Netherlands, Romania, Russia, Slovakia, South Africa, South Korea, Spain, Sweden, Turkey (Türkiye), United Kingdom
Collaborators--

Timeline

Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedApr 30, 2012
Enrollment StartJul 13, 2012
Primary CompletionSep 27, 2019
TodayJul 2, 2026
Enrollment to primary: 7.2 yearsPosted 14.2 years ago

Interventions

Bevacizumabdrug

Bevacizumab will be administered at 7.5 or 15 milligrams per kilogram (mg/kg) intravenously every 3 weeks (Q3W), or 5 or 10 mg/kg intravenously every 2 weeks (Q2W).